Gonorrhoea is a major public health concern globally. Increasing incidence and sporadic ceftriaxone-resistant cases, including treatment failures, are growing concerns. The 2020 European gonorrhoea guideline provides up-to-date evidence-based guidance regarding the diagnosis and treatment of gonorrhoea. The updates and recommendations emphasize significantly increasing gonorrhoea incidence; broad indications for increased testing with validated and quality-assured nucleic acid amplification tests (NAATs) and culture; dual antimicrobial therapy including high-dose ceftriaxone and azithromycin (ceftriaxone 1 g plus azithromycin 2 g) OR ceftriaxone 1 g monotherapy (ONLY in well-controlled settings, see guideline for details) for uncomplicated gonorrhoea when the antimicrobial susceptibility is unknown; recommendation of test of cure (TOC) in all gonorrhoea cases to ensure eradication of infection and identify resistance; and enhanced surveillance of treatment failures when recommended treatment regimens have been used. Improvements in access to appropriate testing, test performance, diagnostics, antimicrobial susceptibility surveillance and treatment, and follow-up of gonorrhoea patients are essential in controlling gonorrhoea and to mitigate the emergence and/or spread of ceftriaxone resistance and multidrug-resistant and extensively drug-resistant gonorrhoea. This review provides the detailed background, evidence base and discussions, for the 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults (Unemo M, et al. Int J STD AIDS. 2020).
UnemoMSeifertHSHookEW3rd, et al. Gonorrhoea. Nat Rev Dis Primers2019; 5: 79.
2.
HookEWIIIHandsfieldHH. Gonococcal infections in the adult. In Holmes KK, Sparling PF, (eds.), Sexually transmitted diseases. 4th ed. New York, NY. McGraw Hill 2008. 627–645.
3.
BignellCUnemoM, European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS2013; 24: 85–92.
4.
CornelisseVJWilliamsonDZhangL, et al. Evidence for a new paradigm of gonorrhoea transmission: cross-sectional analysis of Neisseria gonorrhoeae infections by anatomical site in both partners in 60 male couples. Sex Transm Infect2019; 95: 437–442.
5.
CornelisseVJZhangLLawM, et al. Concordance of gonorrhoea of the rectum, pharynx and urethra in same-sex male partnerships attending a sexual health service in Melbourne, Australia. BMC Infect Dis2018; 18: 95.
6.
CornelisseVJBradshawCSChowEPF, et al. Oropharyngeal gonorrhea in absence of urogenital gonorrhea in sexual network of male and female participants, Australia, 2018. Emerging Infect Dis2019; 25: 1373–1376.
7.
FairleyCKCornelisseVJHockingJS, et al. Models of gonorrhoea transmission from the mouth and saliva. Lancet Infect Dis2019; 19: e360–e366.
8.
ChowEPFMaddafordKTrumpourS, et al. Translating mouthwash use for gonorrhoea prevention into a public health campaign: identifying current knowledge and research gaps. Sex Health 2019; 16: 433–441.
9.
ChowEPFWalkerSHockingJS, et al. A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (oral mouthwash use to eradicate gonorrhoea) study protocol. BMC Infect Dis2017; 17: 456.
10.
RowleyJVander HoornSKorenrompE, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ2019; 97: 548–562.
RisleyCLWardHChoudhuryB, et al. Geographical and demographic clustering of gonorrhoea in London. Sex Transm Infect2007; 83: 481–487.
14.
ReddyBSNKhandpurSSethiS, et al. Gonococcal infections. In: Gupta S and Kumar B (eds) Sexually transmitted infections. 2nd ed. New Delhi, India: Elsevier, 2012, pp.473–493.
15.
SherrardJBarlowD.Gonorrhoea in men: clinical and diagnostic aspects. Genitourin Med1996; 72: 422–426.
16.
LewisDABondMButtKD, et al. A one-year survey of gonococcal infection seen in the genitourinary medicine department of a London district general hospital. Int J STD AIDS1999; 10: 588–594.
17.
BarlowDPhillipsI.Gonorrhoea in women: diagnostic, clinical and laboratory aspects. Lancet1978; 1: 761–764.
18.
KentCKChawJKWongW, et al. Prevalence of rectal, urethral and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San francisco, California 2003. Clin Infect Dis2005; 41: 67–74.
19.
PetersRPHNijstenNMutsaersJ, et al. Screening of oropharynx and anorectum increases prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors. Sex Transm Dis2011; 38: 783–787.
20.
BleichATSheffieldJSWendelGDJr, et al. Gonococcal infection in women. Obstet Gynecol2012; 119: 597–602.
21.
O’brienJPGoldenbergDLRicePA.Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine1983; 62: 395–406.
22.
BelkacemACaumesEOuanichJ, et al. Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009–2011. Sex Transm Infect2013; 89: 613–615.
23.
RothAMattheisCMuenznerP, et al. Innate recognition by neutrophil granulocytes differs between Neisseria gonorrhoeae strains causing local or disseminating infections. Infect Immun2013; 81: 2358–2370.
24.
BirrellJMGunathilakeMSingletonS, et al. Characteristics and impact of disseminated gonococcal infection in the “top end” of Australia. Am J Trop Med Hyg2019; 101: 753–760.
AbrahaMEgli-GanyDLowN.Epidemiological, behavioural, and clinical factors associated with antimicrobial-resistant gonorrhoea: a review. F1000Res2018; 7: 400.
27.
KirkcaldyRDWestonESeguradoAC, et al. Epidemiology of gonorrhoea: a global perspective. Sex Health2019; 16: 401–411.
28.
GrentzerJMPeipertJFZhaoQ, et al. Risk-based screening for Chlamydia trachomatis and Neisseria gonorrhoeae prior to intrauterine device insertion. Contraception2015; 92: 313–318.
29.
SufrinCBAverbachSH.Testing for sexually transmitted infections at intrauterine device insertion: an evidence-based approach. Clin Obstet Gynecol2014; 57: 682–693.
30.
UnemoM andIsonC. Gonorrhoea. In: Unemo M and Ballard R (eds) Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus. 2nd ed. Geneva, Switzerland: World Health Organization, 2013, pp.21–54.
31.
TaylorSNDiCarloRPMartinDH.Comparison of methylene blue/gentian violet stain to gram’s stain for the rapid diagnosis of gonococcal urethritis in men. Sex Trans Dis2011; 38: 995–996.
32.
ThorleyNRadcliffeK.The performance and clinical utility of cervical microscopy for the diagnosis of gonorrhoea in women in the era of the NAAT. Int J STD AIDS2015; 26: 656–660.
33.
JephcottAE.Microbiological diagnosis of gonorrhoea. Genitourin Med1997; 73: 245–252.
34.
ForniJMilesKHamillM.Microscopy detection of rectal gonorrhoea in asymptomatic men. Int J STD AIDS2009; 20: 797–798.
35.
WindCMSchim van der LoeffMFUnemoM, et al. Test of cure for anogenital gonorrhoea using modern RNA-based and DNA-based nucleic acid amplification tests: a prospective cohort study. Clin Infect Dis2016; 62: 1348–1355.
36.
WhileyDMGoireNLahraMM, et al. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother2012; 67: 2059–2061.
37.
CookRLHutchisonSLØstergaardL, et al. Systematic review: non-invasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med2005; 142: 914–925.
38.
WhileyDMGarlandSMHarnettG, et al. Exploring ‘best practice’ for nucleic acid detection of Neisseria gonorrhoeae. Sex Health2008; 5: 17–23.
39.
FiferHSaundersJSoniS, et al. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS2020; 31: 4–15.
Centers for disease control and prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae–2014. MMWR Recomm Rep2014; 63: 1–19.
42.
HarrymanLScofieldSMacleodJ, et al. Comparative performance of culture using swabs transported in Amies medium and the Aptima Combo 2 nucleic acid amplification test in detection of Neisseria gonorrhoeae from genital and extra-genital sites: a retrospective study. Sex Transm Infect2012; 88: 27–31.
43.
Van DyckEIevenMPattynS, et al. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture and three nucleic acid amplification tests. J Clin Microbiol2001; 39: 1751–1756.
44.
Van Der PolBFerreroDVBuck-BarringtonL, et al. Multicenter evaluation of the BDProbeTec ET system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical and male urethral swabs. J Clin Microbiol2001; 39: 1008–1016.
45.
MoncadaJSchachterJHookEW3rd, et al. The effect of urine testing in evaluations of the sensitivity of the Gen-Probe APTIMA combo 2 assay on endocervical swabs for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Transm Dis2004; 31: 273–277.
46.
CherneskyMAMartinDHHookEW, et al. Ability of new APTIMA CT and APTIMA GC assays to detect Chlamydia trachomatis and Neisseria gonorrhoeae in male urine and urethral swabs. J Clin Microbiol2005; 43: 127–131.
47.
SchachterJCherneskyMAWillisDE, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Trans Dis2005; 32: 725–728.
48.
IsonC.GC NAATs: is the time right?Sex Transm Infect2006; 82: 515.
49.
CornelisseVJChowEPHuffamS, et al. Increased detection of pharyngeal and rectal gonorrhea in men who have sex with men after transition from culture to nucleic acid amplification testing. Sex Transm Dis2017; 44: 114–117.
50.
Van Der PolBHookEW3rdWilliamsJA, et al. Performance of the BD CTQx and GCQx amplified assays on the BD viper LT compared with the BD viper XTR system. Sex Transm Dis2015; 42: 521–523.
51.
GeelenTHRossenJWBeerensAM, et al. Performance of Cobas(R) 4800 and m2000 real-time assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and self-collected vaginal specimen. Diagn Microbiol Infect Dis2013; 77: 101–105.
52.
BachmannLHJohnsonREChengH, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol2010; 48: 1827–1832.
53.
BachmannLHJohnsonREChengH, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae oropharyngeal infections. J Clin Microbiol2009; 47: 902–907.
54.
LunnyCTaylorDHoangL, et al. Self-collected versus clinician-collected sampling for chlamydia and gonorrhea screening: a systemic review and meta-analysis. PLoS One2015; 10: e0132776.
55.
CoorevitsLTraenABingéL, et al. Identifying a consensus sample type to test for Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis and human papillomavirus. Clin Microbiol Infect2018; 24: 1328–1332.
56.
StewartCMSchoemanSABoothRA, et al. Assessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy study. BMJ2012; 345: e8107.
57.
Van Der PolBTaylorSNLiesenfeldO, et al. Vaginal swabs are the optimal specimen for detection of genital Chlamydia trachomatis or Neisseria gonorrhoeae using the Cobas 4800 CT/NG test. Sex Transm Dis2013; 40: 247–250.
58.
PalmerHMallinsonHWoodRL, et al. Evaluation of the specificities of five DNA amplification methods for the detection of Neisseria gonorrhoeae. J Clin Microbiol2003; 41: 835–837.
59.
TabriziSNUnemoMLimniosAE, et al. Evaluation of six commercial nucleic acid amplification tests for the detection of Neisseria gonorrhoeae and other Neisseria species. J Clin Microbiol2011; 49: 3610–3615.
60.
GolparianDBorängSSundqvistM, et al. Evaluation of the new BD max GC real-time PCR assay, analytically and clinically as a supplementary test for the BD ProbeTec GC Qx amplified DNA assay, for molecular detection of Neisseria gonorrhoeae. J Clin Microbiol2015; 53: 3935–3937.
61.
PriestDOngJJChowEPF, et al. Neisseria gonorrhoeae DNA bacterial load in men with symptomatic and asymptomatic gonococcal urethritis. Sex Transm Infect2017; 93: 478–481.
62.
ChowEPTabriziSNPhillipsS, et al. Neisseria gonorrhoeae bacterial DNA load in the pharynges and saliva of men who have sex with men. J Clin Microbiol2016; 54: 2485–2490.
63.
Page-ShaferKGravesAKentC, et al. Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhoea in men who have sex with men. Clin Infect Dis2002; 34: 173–176.
64.
McNallyLPTempletonDJJinF, et al. Low positive predictive value of a nucleic acid amplification test for nongenital Neisseria gonorrhoeae infection in homosexual men. Clin Infect Dis2008; 47: e25–e27.
65.
SchachterJMoncadaJLiskaS, et al. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections in the oropharynx and rectum in men who have sex with men. Sex Trans Dis2008; 35: 637–642.
66.
OtaKVTamariIESmiejaM, et al. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in pharyngeal and rectal specimens using the BD Probetec ET system, the Gen-Probe Aptima Combo 2 assay and culture. Sex Transm Infect2009; 85: 182–186.
67.
MimiagaMJHelmsDJReisnerSL, et al. Gonococcal, chlamydia, and syphilis infection positivity among MSM attending a large primary care clinic, Boston, 2003 to 2004. Sex Transm Dis2009; 36: 507–511.
68.
MitchellMRaneVFairleyCK, et al. Sampling technique is important for optimal isolation of pharyngeal gonorrhoea. Sex Transm Infect2013; 89: 557–560.
69.
SmithDWTapsallJWLumG.Guidelines for the use and interpretation of nucleic acid detection tests for Neisseria gonorrhoeae in Australia: a position paper on behalf of the public health laboratory network. Commun Dis Intell2005; 29: 358–365.
70.
HughesGIsonCFieldN, et al. Guidance for the detection of gonorrhoea in England. London: Public Health England.
71.
PopeCFHayPAlexanderS, et al. Positive predictive value of the Becton Dickinson VIPER system and the ProbeTec GC Q x assay, in extracted mode, for detection of Neisseria gonorrhoeae. Sex Transm Infect2010; 86: 465–469.
72.
WhileyDMLahraMM; National Neisseria Network.National Neisseria network. Review of 2005 public health laboratory network Neisseria gonorrhoeae nucleic acid amplification tests guidelines. Commun Dis Intell Q Rep2015; 39: E42–E45.
73.
FieldNCliftonSAlexanderS, et al. Confirmatory assays are essential when using molecular testing for Neisseria gonorrhoeae in low-prevalence settings: insights from the third national survey of sexual attitudes and lifestyles (natsal-3). Sex Transm Infect2015; 91: 338–341.
74.
GuyRJCauserLMKlausnerJD, et al. Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infections. Sex Transm Infect2017; 93: S16–S21.
75.
ToskinIGovenderVBlondeelK, et al. Call to action for health systems integration of point-of-care testing to mitigate the transmission and burden of sexually transmitted infections. Sex Transm Infect. Sex Transm Infect 2020; 96: 342–347.
76.
GaydosCAMelendezJH.Point-by-point progress: gonorrhea point of care tests. Expert Rev Mol Diagn2020; 1–11.
77.
SadiqSTMazzaferriFUnemoM.Rapid accurate point-of-care tests combining diagnostics and antimicrobial resistance prediction for Neisseria gonorrhoeae and Mycoplasma genitalium. Sex Transm Infect2017; 93: S65–S68.
78.
LowNUnemoM.Molecular tests for the detection of antimicrobial resistant Neisseria gonorrhoeae: when, where, and how to use?Curr Opin Infect Dis2016; 29: 45–51.
79.
DonàVLowNGolparianD, et al. Recent advances in the development and use of molecular tests to predict antimicrobial resistance in Neisseria gonorrhoeae. Expert Rev Mol Diagn2017; 17: 845–859.
80.
van LiereGAFSDukers-MuijrersNHTMLevelsL, et al. High proportion of anorectal Chlamydia trachomatis and Neisseria gonorrhoeae after routine universal urogenital and anorectal screening in women visiting the sexually transmitted infection clinic. Clin Infect Dis2017; 64: 1705–1710.
81.
van LiereGAHoebeCJNiekampAM, et al. Standard symptom- and sexual history-based testing misses anorectal Chlamydia trachomatis and Neisseria gonorrhoeae infections in swingers and men who have sex with men. Sex Transm Dis2013; 40: 285–289.
82.
van LiereGAHoebeCJDukers-MuijrersNH.Evaluation of the anatomical site distribution of chlamydia and gonorrhoea in men who have sex with men and in high-risk women by routine testing: cross-sectional study revealing missed opportunities for treatment strategies. Sex Transm Infect2014; 90: 58–60.
83.
AnschuetzGLPaulukonisEPowersR, et al. Extragenital screening in men who have sex with men diagnoses more chlamydia and gonorrhea cases than urine testing alone. Sex Transm Dis2016; 43: 299–301.
84.
MoncadaJShayevichCPhilipSS, et al. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and oropharyngeal swabs and urine specimens from men who have sex with men with Abbott’s M2000 RealTime. Sex Transm Dis2015; 42: 650–651.
85.
den HeijerCDJHoebeCJPAvan LiereGAFS, et al. A comprehensive overview of urogenital, anorectal and oropharyngeal Neisseria gonorrhoeae testing and diagnoses among different STI care providers: a cross-sectional study. BMC Infect Dis2017; 17: 290.
86.
TrebachJDChaulkCPPageKR, et al. Neisseria gonorrhoeae and Chlamydia trachomatis among women reporting extragenital exposures. Sex Transm Dis2015; 42: 233–239.
87.
DombrowskiJC.Do women need screening for extragenital gonococcal and chlamydial infections?Sex Transm Dis2015; 42: 240–242.
88.
WallaceHLoftus-KeelingMWardH, et al. O022 rectal chlamydia infection in women – have we been missing the point?Sex Transm Infect2016; 92: A8.
89.
WilsonJWallaceHLoftus-KeelingM, et al. 4 Clinician-taken extra-genital samples for gonorrhoea and chlamydia in women and MSM compared with self-taken samples analysed separately and self-taken pooled samples. Sex Transm Infect2017; 93: A26.
90.
SultanBWhiteJAFishR, et al. The “3 in 1” study: pooling self-taken pharyngeal, urethral, and rectal samples into a single sample for analysis for detection of Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men. J Clin Microbiol2016; 54: 650–656.
91.
DurukanDReadTRHBradshawCS, et al. Pooling pharyngeal, anorectal and urogenital samples for screening asymptomatic men who have sex with men for Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol2020; 58: e01969.
92.
BadmanSGBellSFEDeanJA, et al. Reduced sensitivity from pooled urine, pharyngeal and rectal specimens when using a molecular assay for the detection of chlamydia and gonorrhoea near the point of care. Sex Health2020; 17: 15–21.
93.
De BaetselierIVuylstekeBYayaI, et al. To Pool or not to pool samples for sexually transmitted infections detection in men who have sex with men? An evaluation of a new pooling method using the GeneXpert instrument in West-Africa. Sex Transm Dis 2020; 47: 556–561.
94.
UnemoMShaferWM.Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev2014; 27: 587–613.
95.
GolparianDHarrisSRSánchez-BusóL, et al. Genomic evolution of Neisseria gonorrhoeae since the preantibiotic era (1928–2013): antimicrobial use/misuse selects for resistance and drives evolution. BMC Genomics2020; 21: 116.
96.
UnemoMNicholasRA.Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol2012; 7: 1401–1422.
97.
UnemoM.Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis2015; 15: 364.
98.
RomanowskiBRobinsonJWongT. Gonococcal infections chapter. In: Canadian guidelines on sexually transmitted infections. Ottawa, ON: Public Health Agency of Canada, 2013.
99.
Australasian Sexual Health Alliance (ASHA). Gonorrhoea. In: Australian STI management guidelines for use in primary care. Australia: ASHA, 2018.
100.
World Health Organization (WHO). WHO guidelines for the treatment of Neisseria gonorrhoeae. Geneva: WHO, 2016.
101.
BarbeeLASogeOOHolmesKK, et al. In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae. J Antimicrob Chemother2014; 69: 1572–1578.
102.
PereiraRColeMJIsonCA.Combination therapy for gonorrhoea: in vitro synergy testing. J Antimicrob Chemother2013; 68: 640–643.
103.
WindCMde VriesHJvan DamAP.Determination of in vitro synergy for dual antimicrobial therapy against resistant Neisseria gonorrhoeae using Etest and agar dilution. Int J Antimicrob Agents2015; 45: 305–308.
104.
FuruyaRNakayamaHKanayamaA, et al. In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother2006; 12: 172–176.
105.
SinghVBalaMBhargavaA, et al. In vitro efficacy of 21 dual antimicrobial combinations comprising novel and currently recommended combinations for treatment of drug resistant gonorrhoea in future era. PLoS One2018; 13: e0193678.
106.
KongFYSHornerPUnemoM, et al. Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review. J Antimicrob Chemother2019; 74: 1157–1166.
107.
HarrisSRColeMJSpiteriG, et al. Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey. Lancet Infect Dis2018; 18: 758–768.
108.
BarbeeLAKeraniRPDombrowskiJC, et al. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis2013; 56: 1539–1545.
109.
ColeMJSpiteriGJacobssonS, Euro-GASP Network,et al.Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance. BMC Infect Dis2015; 15: 321.
110.
ColeMJSpiteriGJacobssonS, et al. Overall low extended-spectrum cephalosporin resistance but high azithromycin resistance in Neisseria gonorrhoeae in 24 European countries, 2015. BMC Infect Dis2017; 17: 617.
111.
DayMJSpiteriGJacobssonS, et al. Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. BMC Infect Dis2018; 18: 609.
112.
HornerPJ.Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy. Sex Transm Infect2012; 88: 154–156.
113.
UnemoMClarkeEBoikoI, et al. Adherence to the 2012 European gonorrhoea guideline in the WHO European region according to the 2018-19 international union against sexually transmitted infections European collaborative clinical group gonorrhoea survey. Int J STD AIDS2020; 31: 69–76.
114.
FiferHColeMHughesG, et al. Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study. Lancet Infect Dis2018; 18: 573–581.
115.
RossJDCBrittainCColeM, et al. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet2019; 393: 2511–2520.
116.
TapsallJWSchultzTRLimniosEA, et al. Failure of azithromycin therapy in gonorrhoea and discorrelation with laboratory parameters. Sex Trans Dis1998; 25: 505–508.
117.
ColeMJTanWFiferH, et al. Gentamicin, azithromycin and ceftriaxone in the treatment of gonorrhoea: the relationship between antibiotic MIC and clinical outcome. J Antimicrob Chemother2020; 75: 449–457.
118.
UnemoMWorkowskiK.Dual antimicrobial therapy for gonorrhoea: what is the role of azithromycin?Lancet Infect Dis2018; 18: 486–488.
CrokaertFHublouxACauchieP.A phase I determination of azithromycin in plasma during a 6-week period in normal volunteers after a standard dose of 500mg once daily for 3 days. Clin Drug Investig1998; 16: 161–166.
121.
ZhengSMatznellerPZeitlingerM, et al. Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects. Antimicrob Agents Chemother2014; 58: 6675–6684.
122.
MatznellerPKrasniqiSKinzigM, et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother2013; 57: 1736–1742.
123.
CliftonSTownKFuregatoM, et al. Is previous azithromycin treatment associated with azithromycin resistance in Neisseria gonorrhoeae? A cross-sectional study using national surveillance data in England. Sex Transm Infect2018; 94: 421–426.
124.
KenyonCBuyzeJSpiteriG, et al. Population-level antimicrobial consumption is associated with decreased antimicrobial susceptibility in Neisseria gonorrhoeae in 24 European countries: an ecological analysis. J Infect Dis2020; 221: 1107–1116.
125.
KirkcaldyRDBartocesMGSogeOO, et al. Antimicrobial drug prescription and Neisseria gonorrhoeae susceptibility, United States, 2005–2013. Emerging Infect Dis2017; 23: 1657–1663.
126.
OlesenSWTorroneEAPappJR, et al. Azithromycin susceptibility among Neisseria gonorrhoeae isolates and seasonal macrolide use. J Infect Dis2019; 219: 619–623.
127.
WindCMde VriesESchim van der LoeffMF, et al. Decreased azithromycin susceptibility of Neisseria gonorrhoeae isolates in patients recently treated with azithromycin. Clin Infect Dis2017; 65: 37–45.
128.
UnemoMLahraMMColeM, et al. World health organization global gonococcal antimicrobial surveillance program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sex Health2019; 16: 412–425.
129.
NakayamaSShimutaKFurubayashiK, et al. New ceftriaxone- and multidrug-resistant Neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan. Antimicrob Agents Chemother2016; 60: 4339–4341.
130.
LahraMMMartinIDemczukW, et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerg Infect Dis2018; 24: 735–740.
TerkelsenDTolstrupJJohnsenCH, et al. Multidrug-resistant Neisseria gonorrhoeae infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017. Euro Surveill2017; 22: 17-00659.
133.
PoncinTFouereSBrailleA, et al. Multidrug-resistant Neisseria gonorrhoeae failing treatment with ceftriaxone and doxycycline in France, November 2017. Euro Surveill2018; 23: 1800264.
134.
GolparianDRoseLLynamA, et al. Multidrug-resistant Neisseria gonorrhoeae isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018. Euro Surveill2018; 23: 1800617.
135.
KoKKKChioMTWGohSS, et al. First case of ceftriaxone-resistant multidrug-resistant Neisseria gonorrhoeae in Singapore. Antimicrob Agents Chemother2019; 63: e02624.
136.
EyreDWTownKStreetT, et al. Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Euro Surveill2019; 24: 1900147.
137.
LeeKNakayamaSIOsawaK, et al. Clonal expansion and spread of the ceftriaxone-resistant Neisseria gonorrhoeae strain FC428, identified in Japan in 2015, and closely related isolates. J Antimicrob Chemother2019; 74: 1812–1819.
138.
ChenSCHanYYuanLF, et al. Identification of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain FC428, China. Emerging Infect Dis2019; 25: 1427–1429.
139.
EyreDWSandersonNDLordE, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill2018; 23: 1800323.
140.
JennisonAVWhileyDLahraMM, et al. Genetic relatedness of ceftriaxone-resistant and high-level azithromycin resistant Neisseria gonorrhoeae cases, United Kingdom and Australia, February to April 2018. Euro Surveill2019; 24: 1900118.
141.
Hernando RovirolaCSpiteriGSabidóM, et al. Antimicrobial resistance in Neisseria gonorrhoeae isolates from foreign-born population in the European gonococcal antimicrobial surveillance programme.Sex Transm Infect 2020; 96: 204–210.
142.
ChisholmSMoutonJLewisD, et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?J Antimicrob Chemother2010; 65: 2141–2148.
143.
RobFKlubalováBNyčováE, et al. Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial. Clin Microbiol Infect2020; 26: 207–212.
144.
KirkcaldyRDWeinstockHSMoorePC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis2014; 59: 1083–1091.
145.
BignellCGarleyJ.Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect2010; 86: 422–426.
146.
HandsfieldHHDaluZAMartinDH, et al. Multicenter trial of single-dose azithromycin vs ceftriaxone in the treatment of uncomplicated gonorrhoea. Sex Trans Dis1994; 21: 107–111.
147.
MensforthSRossJDC.Should we still use azithromycin for gonorrhoea treatment?Sex Health2019; 16: 442–448.
148.
GirardDFineganSMDunneMW, et al. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother2005; 56: 365–371.
Di PaoloABarbaraCChellaA, et al. Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacol Res2002; 46: 545–550.
151.
AmsdenGWNafzigerANFouldsG.Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother1999; 43: 163–165.
152.
KongF. Is the current treatment of urogenital and anorectal chlamydia infection appropriate? 2017.
153.
FouldsGJohnsonRB.Selection of dose regimens of azithromycin. J Antimicrob Chemother1993; 31: 39–50.
154.
ReadTRHFairleyCKMurrayGL, et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation. Clin Infect Dis2019; 68: 554–560.
155.
HookEWMartinDHStephensJ, et al. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis2002; 29: 486–490.
156.
TakahashiSKiyotaHItoS, et al. Clinical efficacy of a single two gram dose of azithromycin extended release for male patients with urethritis. Antibiotics (Basel)2014; 3: 109–120.
157.
AlirolEWiTEBalaM, et al. Multidrug-resistant gonorrhea: a research and development roadmap to discover new medicines. PLoS Med2017; 14: e1002366.
158.
TapsallJWNdowaFLewisDA, et al. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther2009; 7: 821–834.
159.
GottliebSLNdowaFHookEW3rd, et al. Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine2020; 38: 4362–4373.
TiplicaGSRadcliffeKEvansC, et al. 2015 European guidelines for the management of partners of persons with sexually transmitted infections. J Eur Acad Dermatol Venereol2015; 29: 1251–1257.
162.
HookEWBehetsFVan DammeK, et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J Infect Dis2010; 201: 1729–1735.
163.
MoranJSLevineWC.Drugs of choice in the treatment of uncomplicated gonococcal infection. Clin Infect Dis1995; 20: S47–S65.
164.
NewmanLMMoranJSWorkowskiKA.Update on the management of gonorrhoea in adults in the United States. Clin Infect Dis2007; 44: S84–S101.
165.
ItoSYasudaMHatazakiK, et al. Microbiological efficacy and tolerability of a single-dose regimen of 1 g of ceftriaxone in men with gonococcal urethritis. J Antimicrob Chemother2016; 71: 2559–2562.
166.
MurataniTInatomiHAndoY, et al. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol2008; 15: 837–842.
167.
Japanese Society of Sexually Transmitted Infections. Gonococcal infection. Sexually transmitted infections, diagnosis and treatment guidelines 2011. Jpn J Sex Transm Dis2011; 22: 52–59 (in Japanese).
168.
BoikoIGolparianDKrynytskaI, et al. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates and treatment of gonorrhoea patients in Ternopil and Dnipropetrovsk regions of Ukraine, 2013–2018. APMIS2019; 127: 503–509.
169.
UnemoMShipitsynaEDomeikaM; Eastern European Sexual and Reproductive Health (EE SRH) Network Antimicrobial Resistance Group. Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 east European countries: implementation of a Neisseria gonorrhoeae antimicrobial susceptibility programme in this region is crucial. Sex Transm Infect2010; 86: 442–444.
170.
TapsallJW.Implications of current recommendations for third-generation cephalosporin use in the WHO Western pacific region following the emergence of multiresistant gonococci. Sex Transm Infect2009; 85: 256–258.
171.
PichicheroMECaseyJR.Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg2007; 136: 340–347.
172.
YatesAB.Management of patients with a history of allergy to beta-lactam antibiotics. Am J Med2008; 121: 572–576.
NovalbosASastreJCuestaJ, et al. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin Exp Allergy2001; 31: 438–443.
175.
RomanoAGaetaFValluzziRL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol2010; 126: 994–999.
176.
MoranJS.Ciprofloxacin for gonorrhea – 250 mg or 500 mg?Sex Transm Dis1996; 23: 165–167.
177.
PondMJHallCLMiariVF, et al. Accurate detection of Neisseria gonorrhoeae ciprofloxacin susceptibility directly from genital and extragenital clinical samples: towards genotype-guided antimicrobial therapy. J Antimicrob Chemother2016; 71: 897–902.
178.
Allan-BlitzLTWangXKlausnerJD.Wild-type gyrase a genotype of Neisseria gonorrhoeae predicts in vitro susceptibility to ciprofloxacin: a systematic review of the literature and meta-analysis. Sex Transm Dis2017; 44: 261–265.
179.
Allan-BlitzLTHumphriesRMHemarajataP, et al. Implementation of a rapid genotypic assay to promote targeted ciprofloxacin therapy of Neisseria gonorrhoeae in a large health system. Clin Infect Dis2017; 64: 1268–1270.
180.
HadadRColeMJEbeyanS, et al. Evaluation of the SpeeDx ResistancePlus® GC and SpeeDx GC 23S 2611 (beta) molecular assays for prediction of antimicrobial resistance/susceptibility to ciprofloxacin and azithromycin in Neisseria gonorrhoeae. J Antimicrob Chemother 2020. In press.
GratrixJBergmanJEganC, et al. Retrospective review of pharyngeal gonorrhea treatment failures in Alberta, Canada. Sex Transm Dis2013; 40: 877–879.
183.
AllenVGMitterniLSeahC, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA2013; 309: 163–170.
184.
BarbeeLANayakSUBlumerJL, et al. A phase 1 pharmacokinetic and safety study of extended-duration, high-dose cefixime for cephalosporin-resistant Neisseria gonorrhoeae in the pharynx. Sex Transm Dis2018; 45: 677–683.
185.
LewisDA.Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains?Sex Transm Infect2015; 91: 234–237.
186.
TaylorSNMarrazzoJBatteigerBE, et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med2018; 379: 1835–1845.
187.
MoranJS.Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important?Sex Transm Dis1995; 22: 39–47.
188.
OtaKVFismanDNTamariIE, et al. Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with men: a 13-year retrospective cohort study. Clin Infect Dis2009; 48: 1237–1243.
189.
FiferHNatarajanUJonesL, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med2016; 374: 2504–2506.
190.
OhnishiMGolparianDShimutaK, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother2011; 55: 3538–3545.
191.
TaylorSNMorrisDHAveryAK, et al. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation. Clin Infect Dis2018; 67: 504–512.
192.
BarbeeLASogeOOMorganJ, et al. Gentamicin alone inadequate to eradicate Neisseria gonorrhoeae from the pharynx. Clin Infect Dis. Epub ahead of print 12 November 2019. DOI:10.1093/cid/ciz1109.
193.
OhnishiMWatanabeYOnoE, et al. Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages. Antimicrob Agents Chemother2010; 54: 1060–1067.
194.
IgawaGYamagishiYLeeKI, et al. Neisseria cinerea with high ceftriaxone MIC is a source of ceftriaxone and cefixime resistance-mediating penA sequences in Neisseria gonorrhoeae. Antimicrob Agents Chemother2018; 62: 17. e02069-17.
195.
SeñaACBachmannLJohnstonC, et al. Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. Lancet Infect Dis. Epub ahead of print 19 June 2020. DOI:10.1016/S1473-3099(20)30171-7.
196.
BlandizziCMaliziaTLupettiA, et al. Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol1999; 70: 960–966.
197.
FouldsGShepardRMJohnsonRB.The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother1990; 25: 73–82.
198.
HanantaIPYDe VriesHJCvan DamAP, et al. Persistence after treatment of pharyngeal gonococcal infections in patients of the STI clinic, Amsterdam, The Netherlands, 2012–2015: a retrospective cohort study. Sex Transm Infect2017; 93: 467–471.
199.
SathiaLEllisBPhillipS, et al. Pharyngeal gonorrhoea – is dual therapy the way forward?Int J STD AIDS2007; 18: 647–648.
200.
ChisholmSAQuayeNColeMJ, et al. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother2011; 66: 592–595.
201.
MannLMKirkcaldyRDPappJR, et al. Susceptibility of Neisseria gonorrhoeae to gentamicin-gonococcal isolate surveillance project, 2015–2016. Sex Transm Dis2018; 45: 96–98.
202.
BalaMSinghVPhilipovaI, et al. Gentamicin in vitro activity and tentative gentamicin interpretation criteria for the CLSI and calibrated dichotomous sensitivity disc diffusion methods for Neisseria gonorrhoeae. J Antimicrob Chemother2016; 71: 1856–1859.
203.
LiuJWXuWQZhuXY, et al. Gentamicin susceptibility of Neisseria gonorrhoeae isolates from 7 provinces in China. Infect Drug Resist2019; 12: 2471–2476.
204.
UnemoMGolparianDLimniosA, et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?Antimicrob Agents Chemother2012; 56: 3603–3609.
205.
YangFYanJZhangJ, et al. Evaluation of alternative antibiotics for susceptibility of gonococcal isolates from China. Int J Antimicrob Agents2020; 55: 105846.
206.
QuayeNColeMJIsonCA.Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime. J Antimicrob Chemother2014; 69: 1568–1571.
207.
Lagacé-WiensPRSAdamHJLaingNM, et al. Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential. J Antimicrob Chemother2017; 72: 2273–2277.
208.
RamusRMSheffieldJSMayfieldJA, et al. A randomised trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhoea in pregnancy. Am J Obstet Gynecol2001; 185: 629–632.
209.
BrocklehurstP.Antibiotics for gonorrhoea in pregnancy. Cochrane Database Syst Rev2002; 2: CD000098.
210.
CaveneeMRFarrisJRSpaldingTR, et al. Treatment of gonorrhea in pregnancy. Obstet Gynecol1993; 81: 33–38.
WiseCMMorrisCRWasilauskasBL, et al. Gonococcal arthritis in an era of increasing penicillin resistance. presentations and outcomes in 41 recent cases (1985–1991). Arch Intern Med1994; 154: 2690–2695.
213.
ThompsonSE.Treatment of disseminated gonococcal infections. Sex Transm Dis1979; 6: 181–184.
214.
HaimoviciRRousselTJ.Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol1989; 107: 511–514.
215.
BazanJAPetersonASKirkcaldyRD, et al. Notes from the field: increase in Neisseria meningitidis-associated urethritis among men at two sentinel clinics – Columbus, Ohio, and Oakland county, Michigan, 2015. MMWR Morb Mortal Wkly Rep2016; 65: 550–552.
216.
BazanJATurnerANKirkcaldyRD, et al. Large cluster of Neisseria meningitidis urethritis in Columbus, Ohio, 2015. Clin Infect Dis2017; 65: 92–99.
217.
RetchlessACKretzCBChangHY, et al. Expansion of a urethritis-associated Neisseria meningitidis clade in the United States with concurrent acquisition of N. gonorrhoeae alleles. BMC Genomics2018; 19: 176.
218.
HjelmevollSOOlsenMESollidJU, et al. Appropriate time for test-of-cure when diagnosing gonorrhoea with a nucleic acid amplification test. Acta Derm Venereol2012; 92: 316–319.
219.
BachmannLHDesmondRAStephensJ, et al. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. J Clin Microbiol2002; 40: 3596–3601.
220.
BuckleyCBeatsonSALimniosA, et al. Whole-genome sequencing as an improved means of investigating Neisseria gonorrhoeae treatment failures. Sex Health2019; 16: 500–507.
